A very small number of cobalt complexes is examined in oncology research. In this work, we investigate the cobalt (III) salen complex MBR-60 that turns out to be a promising anticancer drug. It induces apoptosis in Nalm6 leukemia and BJAB lymphoma cells and overcomes multidrug resistances by blocking the drug efflux pump P-glycoprotein. It further develops the apoptotic effects over the intrinsic pathway. An activation of caspase-3, caspase-8 and caspase-9 can be detected by western blot analysis. The independence of CD95 is shown by similar apoptotic inductions in BJAB and BJAB FADDdn cells. MBR-60 displays synergistic effects with daunorubicin and vincristine and has a selectivity to tumor cells. In comparison to the apoptotic effects of MBR-60 in BJAB lymphoma cells, the cobalt-free ligand 5 does not influence these cells. The research highlights that a cobalt complex has a therapeutic potential for cancer treating with a focus on drug-resistant tumors.

在肿瘤学研究中检查了非常少量的钴配合物。在这项工作中，我们研究了钴（II​​I）塞伦复合物MBR-60，该复合物被证明是一种有前途的抗癌药物。它可诱导Nalm6白血病和BJAB淋巴瘤细胞凋亡，并通过阻断药物外排泵P-糖蛋白克服多药耐药性。它通过内在途径进一步发展凋亡作用。可以通过蛋白质印迹分析检测caspase-3，caspase-8和caspase-9的激活。CD95的独立性由BJAB和BJAB FADDdn细胞中类似的凋亡诱导显示。MBR-60与柔红霉素和长春新碱显示协同作用，对肿瘤细胞具有选择性。与MBR-60的凋亡作用相比在BJAB淋巴瘤细胞中，无钴配体5不会影响这些细胞。该研究突出表明，钴复合物具有针对癌症的治疗潜力，重点是耐药性肿瘤。